Leadership

Make medicine together

Alloy Therapeutics is led by a team that has put hundreds of antibodies into the clinic and has the ability to address the unique challenges with novel and innovative solutions.

Leadership team

Errik Anderson

Founder, CEO, Chairman of Alloy

Bioengineer, entrepreneur, and investor who has founded or co-founded several venture-backed biotech companies, including Adimab, Alloy Therapeutics, Compass Therapeutics, Alector, Arsanis, and Avitide.

Piotr Bobrowicz

President of Alloy

Translational scientist with more than 25 years of hands-on research experience. Co-inventor of more than 40 patent families. Contributed to and led scientific efforts at Compass Therapeutics, Adimab, Merck and GlycoFi, delivering novel drug discovery platforms and clinical programs.

Kent Bondensgaard

SVP, Head of Antibody Discovery Services

Patrick Bradley

Head of Gx Business Unit, Senior Counsel

Fluent in science, business, and law, Patrick’s mission is to make robust transgenic animal models available across the drug discovery ecosystem. He drafts and negotiates collaboration and license agreements involving intellectual property, and liaises with Alloy’s partners as they advance drug candidates toward market authorization.

Joshua Brandt

Head of Legal

Lead counsel & registered patent attorney with 15 years of practice experience in the field of biotechnology research, development, and commercialization. Previously represented large institutions across the Commonwealth of Massachusetts in counsel and business development roles, as well as practiced patent prosecution.

Leigh Doyle

Associate Director, UK Operations and Co-head Alloy UK

Experienced Operations and Administrative Professional with over 10 years of expertise in project coordination, facilities management, and human resources.
Christine Foster

CBO, Genetic Medicines and Head of Corporate Development

Biotech and Pharma industry veteran with 30+ years of experience in licensing, corporate strategy, and M&A. Held key roles at leading companies: Intellia, Metagenomi, Acceleron, Teva, GSK, and Wyeth.

Simon Friedensohn

Senior Director, Machine learning & Data engineering and Co-head Alloy Basel

Scientist and entrepreneur with deep expertise in computational biology and protein engineering. Passionate about building cross-functional teams to deliver cutting-edge solutions for drug discovery. Prior to joining Alloy Therapeutics, Simon co-founded deepCDR Biologics.

Laurel Handler-Vosen

Senior Director, Head of People

People & Talent leader with expertise in building teams and scalable people infrastructure. Previously led the People function at Blank Street and built and scaled teams at Astra.

John "Lippy" Lippincott

SVP, Therapeutic Discovery Strategies

25 years experience in discovering therapeutic antibodies supporting a variety of drug modalities and clinical indications.

Davide Schiavone

Senior Director, Head of Genetically Engineered Organisms and Co-head Alloy UK

Experienced biologist with 15+ years specializing in transgenic animal model generation and genome editing. Highly skilled in CRISPR and advanced technologies for editing human and animal cells, driving innovation in genetic research and therapeutic development.
Mike Schmidt

CSO, Alloy

Experienced leader in biologics discovery and development with track record of advancing monoclonal, bispecific, and cytokine based drugs into the clinic. Previously served as CSO of Ankyra Therapeutics, Head of Research at Compass Therapeutics, and led discovery at Eleven Bio.
Heather Schwoebel

CBO, Head of Antibodies and
Strategic Collaborations

An operator with over 20 years of experience in biotech company formation, operations, alliance management, and business development – Heather enjoys building new things and driving them to profitability. Previous roles were with Verseau Therapeutics, Harbour Antibodies and Atlas Venture.

Richard Shimkets

CEO of Daedamab and Head of Alloy Athens

Inventor and entrepreneur who brings nearly 30 years of experience in drug discovery and technology development, with over 30 issued US patents, served as CEO of Abeome and VP of Drug Discovery at CuraGen.
Victor Stone

Head of Cell Therapies and Head of Alloy Japan

Experienced biotech executive with track record in biotech investments, platform builds and regional ecosystem development. Major platform builds include Takeda-Kyoto University iPS CAR-T platform (now Alloy Cell Therapies) and largest SMOL platform in Japan (now full-service CRO Axcelead).

Jeff Swenson

CFO, Alloy

Leader with 25 years of experience driving companies’ financial success. Responsible for all aspects of Alloy’s financial operations including: financial analysis, budgeting and forecasting, accounting and treasury.
Vinod Vathipadiekal

CSO, Genetic Medicines

Vinod is one of the industry’s leading RNA medicine experts, who has held research leadership roles across RNA and nucleic acid therapeutics programs at biotech and pharma companies and led multiple ASO drugs into clinical trials. Previously, he headed the ASO therapeutic programs in Leal Therapeutics (VP, Head of Nucleic Acid Therapeutics) and Eisai (Director, Head of ASO Therapeutics).
Cédric Weber

Senior Director, Data Science & Bioinformatics and Co-head Alloy Basel

Specializing in immune repertoire analysis, protein engineering and machine learning. Previously a co-founder of deepCDR Biologics, he brings entrepreneurial experience combined with computational and drug discovery expertise to facilitate collaborative progress in therapeutic development.
Dongxing Zha

CEO of Keyway TCR Discovery

Led the ORBIT platform at MD Anderson Cancer Center, a Moon Shots platform focused on biologic and cell-based therapies, where he oversaw the team that advanced the first TCRm to the clinic for the treatment of various hematological malignancies.